D. Dvořáková

发表

A Complex Role for FGF-2 in Self-Renewal, Survival, and Adhesion of Human Embryonic Stem Cells

Š. Pospíšilová, V. Kríz, A. Hampl, 2009, Stem cells.

Digital PCR can provide improved BCR-ABL1 detection in chronic myeloid leukemia patients in deep molecular response and sensitivity of standard quantitative methods using EAC assays

D. Dvořáková, Z. Ráčil, Dagmar Smitalova, 2021, Practical laboratory medicine.

Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations

D. Dvořáková, J. Mayer, Z. Ráčil, 2012, Molecular Diagnosis & Therapy.

Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry

P. Šimara, S. Stejskal, I. Koutná, 2014 .

Perioperative interstitial CT-based brachytherapy boost in breast cancer patients with breast conservation after neoadjuvant chemotherapy.

K. Stastný, D. Dvořáková, J. Vaňásek, 2012, Neoplasma.

A real-time (PCR) for a real life…? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice.

Z. Bortlíček, Š. Pospíšilová, M. Navrátil, 2012, Experimental hematology.

Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects

P. Valent, H. Herrmann, I. Sadovnik, 2016, Oncotarget.

Prospective analysis of low-level BCR–ABL1 T315I mutation in CD34 + cells of patients with de novo chronic myeloid leukemia

D. Dvořáková, J. Mayer, Z. Ráčil, 2014, Leukemia & lymphoma.

Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials

L. Dušek, H. Klamová, J. Mužík, 2013, Leukemia & lymphoma.

BCR–ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response

P. Šimara, S. Stejskal, I. Koutná, 2012, Leukemia & lymphoma.

Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML

D. Dvořáková, J. Mayer, Z. Ráčil, 2015, International Journal of Hematology.

Real-Time PCR Diagnostics Failure Caused by Nucleotide Variability within Exon 4 of the Human Cytomegalovirus Major Immediate-Early Gene

D. Dvořáková, J. Vorlíc̆ek, J. Mayer, 2007, Journal of Clinical Microbiology.

Identification of somatic hypermutations in the TP53 gene in B-cell chronic lymphocytic leukemia.

Š. Pospíšilová, J. Šmardová, B. Tichy, 2008, Molecular immunology.

Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment

Š. Pospíšilová, J. Šmardová, D. Dvořáková, 2006, Leukemia.

Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia

D. Dvořáková, J. Vorlíc̆ek, M. Doubek, 2006, Bone Marrow Transplantation.

Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene

D. Dvořáková, J. Mayer, Z. Ráčil, 2013, Leukemia & lymphoma.

Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels

L. Dušek, H. Klamová, M. Karas, 2013, Cancer medicine.

Analysis of Mutations in the BCR-ABL1 Kinase Domain, Using Direct Sequencing

D. Dvořáková, J. Mayer, Z. Ráčil, 2012, Molecular Diagnosis & Therapy.

Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.

D. Dvořáková, J. Mayer, Z. Ráčil, 2012, Molecular diagnosis & therapy.

A Case of a Novel PML/RARA Short Fusion Transcript with Truncated Transcription Variant 2 of the RARA Gene

D. Dvořáková, M. Doubek, J. Mayer, 2010, Molecular Diagnosis & Therapy.

Imatinib as the first‐line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?

L. Dušek, H. Klamová, J. Březinová, 2011, American journal of hematology.

Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse

J. Kissová, D. Dvořáková, J. Mayer, 2011, International journal of laboratory hematology.

Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.

H. Klamová, J. Moravcová, D. Dvořáková, 2010, Experimental hematology.

Monitoring of Epstein–Barr virus load in patients after allogeneic hematopoietic stem cell transplantation

D. Dvořáková, J. Mayer, M. Lengerova, 2012, Infection.

Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.

J. Fajkus, L. Fajkusová, J. Fulnecek, 2000, Blood cells, molecules & diseases.

CEBPA Gene Mutational Status

D. Dvořáková, J. Mayer, F. Rázga, 2012, Molecular Diagnosis & Therapy.

CEBPA Gene Mutational Status

D. Dvořáková, J. Mayer, F. Rázga, 2012, Molecular Diagnosis & Therapy.

Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.

H. Klamová, J. Březinová, K. Michalová, 2010, Neoplasma.

Haplotype distribution at the phenylalanine hydroxylase locus in PKU families from the Moravian area of Czechoslovakia

L. Kozák, D. Dvořáková, J. Kamarýt, 1993, Journal of Inherited Metabolic Disease.

Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia

A. Hampl, P. Dvořák, D. Dvořáková, 2003, Leukemia.

Novel complex mutation in NPM1 gene in patient with acute myeloid leukemia

D. Dvořáková, J. Mayer, Z. Ráčil, 2017, Leukemia & lymphoma.

Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations

D. Dvořáková, J. Mayer, Z. Ráčil, 2013, Leukemia & lymphoma.

A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations

D. Dvořáková, J. Pospíšilová, J. Mayer, 2009, Leukemia.

Phenylketonuria mutations and their relation to RFLP haplotypes at the PAH locus in Czech PKU families

L. Kozák, L. Fajkusová, V. Romano, 1995, Human Genetics.

The BCR–ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy

Š. Pospíšilová, J. Šmardová, D. Dvořáková, 2013, Leukemia & lymphoma.

Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy

D. Dvořáková, J. Mayer, Z. Ráčil, 2012, American journal of hematology.

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.

Paul Metcalfe, Helen E White, Susan Branford, 2010, Blood.

Interleukin-2 activation of haematopoietic stem cells.

L. Dušek, R. Hájek, M. Penka, 2002, Acta medica Austriaca.

Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient‐specific NPM1 mutations

D. Dvořáková, J. Mayer, Z. Ráčil, 2010, American journal of hematology.

[Invasive aspergillosis in hematooncological patients: advantages and disadvantages of various diagnostic methods, treatment options and financial costs of therapy].

M. Navrátil, D. Dvořáková, J. Vorlíc̆ek, 2008, Vnitrni lekarstvi.

Significance of qualitative PCR detection method for pre-emptive therapy of cytomegalovirus infection in patients after allogeneic hematopoietic stem cell transplantation--single-centre experience.

D. Dvořáková, J. Mayer, Z. Ráčil, 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2

M. Cazzola, C. Bock, M. Steurer, 2013, PloS one.

The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population†

D. Dvořáková, J. Mayer, Z. Ráčil, 2010, American journal of hematology.

Clinical significance of genetic aberrations in secondary acute myeloid leukemia

A. Stukalov, M. Cazzola, J. Colinge, 2012, American journal of hematology.

FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemias

A. Hampl, P. Dvořák, D. Dvořáková, 2001, Leukemia.

Expression and Potential Role of Fibroblast Growth Factor 2 and Its Receptors in Human Embryonic Stem Cells

A. Hampl, P. Dvořák, D. Dvořáková, 2005, Stem cells.

Fibroblast growth factor signaling in embryonic and cancer stem cells

Ales Hampl, A. Hampl, P. Dvořák, 2006, FEBS letters.

[Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - laboratory experience].

Š. Pospíšilová, D. Dvořáková, A. Vašíková, 2013, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

The persistence of t(14;18)-bearing cells in lymph nodes of patients with follicular lymphoma in complete remission: the evidence for ‘a lymphoma stem cell’

J. Šmardová, L. Křen, D. Dvořáková, 2009, Leukemia & lymphoma.

Changes in the expression of FGFR3 in patients with chronic myeloid leukaemia receiving transplants of allogeneic peripheral blood stem cells

A. Hampl, J. Fajkus, P. Dvořák, 2001, British journal of haematology.

Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.

Š. Pospíšilová, M. Navrátil, D. Dvořáková, 2011, Neoplasma.

Infusion of HLA-mismatched peripheral blood stem cells duringtreatment AML in elderly patients

D. Dvořáková, J. Mayer, Z. Ráčil, 2014 .

The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice

J. Chovancová, V. Bystrý, D. Dvořáková, 2018, Journal of Cancer Research and Clinical Oncology.

Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients

D. Dvořáková, P. Žák, J. Mayer, 2019, British journal of haematology.

Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.

Martin Klabusay, Michael Doubek, D. Dvořáková, 2009, Experimental hematology.

Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC.

D. Dvořáková, J. Hausnerova, J. Skřičková, 2015, Lung cancer.

Detecting human cytomegalovirus drug resistant mutations and monitoring the emergence of resistant strains using real-time PCR.

D. Dvořáková, J. Mayer, Z. Ráčil, 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status

D. Dvořáková, J. Mayer, Z. Ráčil, 2010, Leukemia & lymphoma.

TaqMan based real time PCR assay targeting EML4-ALK fusion transcripts in NSCLC.

Š. Pospíšilová, D. Dvořáková, J. Skřičková, 2014, Lung cancer.

Changes in the expresion of fgfr 3 in patients with chronic myeloid leukaemia receving transplants of alogenic blood stem cells.

D. Dvořáková, J. Mayer, M. Krejci, 2001 .